chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Headache and fatigue about 3 hours after the shot. (05/03/2021) Fever, body aches, tightness in chest, and wheezing 13 hours after the shot. Treated with Advil. (05/03/2021) Fever, body aches, and extreme shortness of breath the next day. Treated with Advil. (05/04/2021) The day after that, shortness of breath while walking or talking. Trouble breathing and strong upper chest pain when walking 500 feet. (05/05/2021) The shortness of breath continued for about 3 more days after that. (05/06/2021 - 05/08/2021)
Diarrhea; Tired; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of DIARRHOEA (Diarrhea) and FATIGUE (Tired) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced DIARRHOEA (Diarrhea) and FATIGUE (Tired). At the time of the report, DIARRHOEA (Diarrhea) and FATIGUE (Tired) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       The patient knew of others who received Moderna and Pfizer vaccines and experienced diarrhea and tired. No concomitant medications were reported. No treatment information was provided.    This case was linked to MOD21-069669 (E2B Linked Report).; Sender's Comments:  MOD21-069669:patient's case
Reddened area; Whenever I rest left wrist on a keyboard, get an electrical-like shock that goes from elbow to end of fingers; Gave injection somewhat forward of the deltoid muscle; This case was reported by a consumer via call center representative and described the occurrence of erythema of extremities in a 76-year-old patient who received Herpes zoster (Shingrix) for prophylaxis.   On 18th July 2019, the patient received the 2nd dose of Shingrix. On an unknown date, 7 days after receiving Shingrix, the patient experienced erythema of extremities, electric shock sensation and vaccine administered at inappropriate site. On an unknown date, the outcome of the erythema of extremities, electric shock sensation and vaccine administered at inappropriate site were unknown.   It was unknown if the reporter considered the erythema of extremities and electric shock sensation to be related to Shingrix.  Additional details were provided as follows: The patient stated that the pharmacist gave the injection somewhat forward of the deltoid muscle, which led to inappropriate route of vaccination. The patient had a reddened area about 6x8 inches toward the inner aspect of upper arm and got an electrical like shock that goes from elbow to the end of fingers. The patient asked could it hit a nerve.
Tdap (ADACEL) given RA IM - 3min later welts developed at site & pt c/o pruritis. Swollen FNP notified 25mg BENADRYL PO given. 8/17/11 09AM pt has no adverse effects per mother. Welts et itching resolved last NOC.
Symptoms began as expected on the day after the 2nd vaccine, but never went away. The fever (102 degress) subsided, but a continuous headache, varying degrees of dizziness and brain fog (the inability to focus or concentrate) continue uninterrupted. It has now been two weeks since my 2nd vaccination and it is difficult for me to attend meetings or focus and follow up on projects. I continue to experience fatigue, dizziness, pain and stiffness in my neck where it attaches to my head - and low-grade headache. I have NO prescription medications and NO pre-existing conditions. I am taking aspirin or Tylenol or Advil to see if any of them are effective. The neck pain is helped by the over-the-counter pain relievers, but the brain fog and dizziness continue along with a dull headache.
This spontaneous report was received from a female patient of unknown age referring to herself. The patient's pertinent medical history, concurrent conditions, drug reactions/allergies and concomitant medications were not provided. On an unknown date, the patient was vaccinated with ZOSTAVAX (dose, route of administration, Lot # and expiration date were not reported) for prophylaxis. On an unknown date, the patient experienced swelling, warmth and itchiness at the injection site after ZOSTAVAX administration. The outcome of injection site swelling, injection site pruritus and injection site warmth was unknown. The causality between these events and vaccination with ZOSTAVAX was not assessed. There was no product quality complaint involved. Additional information is not expected as there is no contact details.
Pt. had an event of emesis x1, looked shaky, sweaty, and pale. Pt. stated he couldn't see for couple of minutes. Pt. provided with Gatorade and cookies. Pt. feels fine after hydration and food. Pt mentioned he did not eat before vaccine. No allergies, no medical conditions mention. Pt. continue being monitored for 30 minutes. Left clinic stable and stated to feel better. Accompanied by mom.  F/u call was performed. Mom mentioned minor pt. has been fine, only reports arm pain. Reminded mom to seek medical attention if any  other concerns. Advised to get second dose and eat/drink something before getting vaccine.
I obtained a Moderna booster vaccine due to innate IGG subclass immune deficiency.  For 5 days after the vaccine shot, I was extremely nauseated and tired. On the 5/6th day a strong, body-wide itching began under my skin, so badly I couldn't sleep for 3 days, despite being on antihistamines.   Delayed reactions to medicines are typical for me. After 3 sleepless nights, I called Dr, who advised taking 4 Xyzal per day and the maximum amount of Benadryl and Singulair each day.  He also agreed that I should use Diflucan and antifungal creams to treat for a systemic yeast infection.  The maximum antihistamines and antifungals controlled the itching enough to get some sleep.  Still, with treatment, the itching persisted for more than 14 days.  I had felt this body-wide under-skin itching sensation before when I was allergic to a medication or, more mildly, when I had a yeast infection.  We believe the full dose of the Moderna booster diverted my weak immune system entirely away from the usual task of keeping yeast in check, thus letting a body-wide yeast infection take hold. Given the outcome, it may be worth halving the dose of Moderna boosters for immune compromised individuals in order to avoid overwhelming the limits of a curtailed immune systems, allowing other opportunistic infections to take hold.
She was in for a Moderna booster but was administered a partial pfizer. Before vaccinating the vaccinator verbally confirmed that they were administering Pfizer and then partway through the administration the patient said they were there for Moderna. The vaccinator stopped and discarded the rest of the dose.
shortage and I got the second shot about 8-10 months after the first; This case was reported by a consumer via interactive digital media and described the occurrence of product supply issue in a patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (1st dose received in 2018).   On an unknown date, the patient received the 2nd dose of Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced product supply issue. On an unknown date, the outcome of the product supply issue was unknown.  Additional details were provided as follows: The reporter was the patient. The age at vaccination was not reported. The reporter stated that, due to shortage, got 2nd dose of Shingrix vaccine about 8 to 10 months after the first, which led to product supply issue. The patient had 1st dose about 3 months ago.
We gave an CPox vaccine subcutaneous in the left thigh with an Expire Date of : 09/28/2022
worst headache of my life/ dizziness / pressure in head / 103 temp All lasted for two weeks Still come and go
This case was reported by a healthcare professional and described the occurrence of high fever in a 37-year-old female subject who was vaccinated with FLULAVAL , pneumococcal vaccine and unspecified PNEUMOVAX. Concurrent medical conditions included chronic back pin. Concurrent medications included NSAIDS. On 13 October 2008 at 09:30, the subject received a dose of FLULAVAL (.5 ml, unknown, unknown arm) and her 1st dose of PNEUMOVAX (unknown, unknown arm). On 15 October 2008, 2 days after vaccination with FLULAVAL, and PNEUMOVAX, the subject experienced high fever, arm swollen, arms redness and hot to touch. The reporting healthcare professional stated the subject received a FLULAVAL and PNEUMOVAX vaccine on the same day and in the same arm. After two days, the subject reported high fever, and a red swollen arm that was hot to touch. She was seen at the emergency department. No other information was provided. At the time of reporting the events were unresolved. The healthcare professional considered the events were possibly related to vaccination with FLULAVAL and PNEUMOVAX.
3 minutes after vaccination, I started to feel warm, sweaty, and tingling sensation. On-site nurses noticed I started to look pale and clammy and took me into evaluation room and checked my vitals. My vitals came back with low blood pressure and low oxygen levels. After resting and a cup of water, my vitals became all normal.
Pt. states that after receiving the 1st dose of J&J 08/04/2021, started experiencing symptoms of severe confused 24hrs sleep, Covid symptoms (tested Negative) 08/09/2021.  Still continuing experiencing symptoms. No known Primary visit.
3mo child rec'd OPV/DTP immun, developed wheezing, screaming episode for @ 3 hrs & lethargy; Child was asymptomatic p/12 hrs;
patient had a heart attack from 90% blockage of artery; patient had a heart attack from 90% blockage of artery; 10Mar2021 10:30 1st dose/31Mar2021 10:30 2nd dose/ COVID-19 sentinel type of nasal swab on 07Jun2021 result was positive; COVID-19 sentinel type of nasal swab result was positive; This is a spontaneous report from a contactable consumer (patient).  A 64-year-old male patient received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection), via an unspecified route of administration, administered in Arm Right on 10Mar2021 10:30 (Lot Number: EN6199) (at the age of 63-year-old) as dose 1, single, via an unspecified route of administration, administered in Arm Right on 31Mar2021 10:30 (Lot Number: EP6955) (at the age of 63-year-old) as dose 2, single for COVID-19 immunization.  The patient medical history was not reported. Concomitant medications included cetirizine hydrochloride (ZYRTEC); mometasone furoate (FLONASE); naproxen; omeprazole (PROTONIX).  The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine.  There were no known allergies.  The most recent COVID-19 vaccine was administered in pharmacy or drug store.  The patient had a heart attack from 90% blockage of artery on 20Apr2021 21:00, with placement of 2 stents which resulted in: Emergency room/department or urgent care, Hospitalization, Life threatening illness (immediate risk of death from the event).  The patient was hospitalized for 2 days in 2021.  Prior to vaccination, the patient was not diagnosed with COVID-19.  The patient had COVID-19 sentinel type of nasal swab on 07Jun2021 result was positive.  Outcome of 'patient had a heart attack from 90% blockage of artery' was resolved in 2021 while outcome of the other events was unknown.
The initial symptoms started out as the typical potential side effects such as muscle aches, low grade fever, headache, and overall malaise. The symptoms progressed throughout the evening of the vaccine administration as pretty intense myalgia mostly in lower extremities. On day 3 post vaccine as I recovered from the typical symptoms I noticed some minor weakness in my legs as I resumed normal activity. That progressed to muscle spasms all over my body that were like rapid fire from one area to the next. It started primarily in my right thigh but then moved all over to upper and lower body as well as left and right sides of the body. This did not hurt but was a bit concerning and definitely out of the norm. I would say the spasms peaked on days 4-5 post vaccination and then gradually decreased in frequency over the following week. Each day got a little better until I had very intermittent spasms in my left shoulder until they went away completely.
Client was given a pediatric Hepatitis A vaccine and should have been given an adult Hepatitis A vaccine.
Angioedema of arm, face, and tongue; Difficulty swallowing; A spontaneous report was received from a physician concerning a 46-year-old female patient who received Moderna's COVID-19 Vaccine (mRNA-1273) and developed angioedema arm, face, and tongue and difficulty swallowing probably due to swelling.    The patient's medical history, as provided by the reporter, included penicillin allergy, seasonal allergies, dermatological fillers and collagen fillers. Concomitant medications included Redopx and Aloim.   On 12 Jan 2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Lot 041L20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection.   On 12 Jan 2021, after receiving the vaccine, the patient had swelling, angioedema of the arm, face and tongue. She also had difficulty swallowing, probably due to the swelling per the reporter. Treatment for the event included prednisone and diphenhydramine.   Action taken with mRNA-1273 in response to the events was not reported.   The outcome of the events, developed angioedema arm, face, and tongue and difficulty swallowing probably due to swelling, were considered resolved on an unknown date.; Reporter's Comments: This case concerns a 46-year-old female patient with relevant medical history of penicillin allergy, seasonal allergies, dermatological fillers and collagen fillers who received their first of two planned doses of mRNA-1273 (Lot 041L20A) intramuscularly in the left arm for prophylaxis of COVID-19 infection. Patient experienced the serious unlisted event of angioedema of the arm, face, and tongue and serious unlisted event of difficulty swallowing probably due to swelling. Treatment for the events included prednisone and diphenhydramine which resolved the events. Based on the temporal association between the use of the product and the events occurring after receiving the vaccine, a causal relationship cannot be excluded and the events of angioedema of the arm, face, and tongue and difficulty swallowing are possibly related to the product.
Information has been received from a physician concerning a 29 year old male with no known allergies and a history of "class 2 TB" who on 28 Jul 2006 at 15:30 was vaccinated SC with a dose of MMR II, it was reported that the patient may have received a previous dose of the vaccine. Concomitant vaccination included a dose of DPT (manufacturer unspecified). There was no illness at the time of vaccination. On 11 Aug 2006, the patient presented to the physician's office with a few day history of slightly itchy maculopapular rash on his face and neck, a fever of 100 degreed F, and a sore throat. A white blood cell-viral count was performed: 5,700 (units unspecified), patient was diagnosed with viral exanthema vs. allergic reaction as the rash was itchy. The patient recovered don 13 Aug 2006. The patient returned on his own one month later and got another dose of MMRII and he "did fine". There was no product quality complaint involved. Additional information is not expected.
Elevated heart rate/pulse of 120 while resting (I was woken up from my sleep with my heart racing, low grade fever 99.7-100.0 F). After a few minutes the heart rate fell to 90. During the next day (05/01/ 2021) pulse was higher than normal for me, while resting (around 90). The night of 05/02/2021 I had another similar event.; was woken up with my heart racing, with a pulse of 120 for a few minutes. Similar events during the night of 05/06/21 ( measured  pulse of 100) and the night of 05/08/2021 (measured  pulse of 100).
This is a spontaneous report received from a contactable reporter(s) (Other HCP). The reporter is the patient. A 38 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 05Feb2021 19:00 (Lot number: EL9262) at the age of 38 years as dose 2, single and intramuscular, administered in arm left, administration date 17Jan2021 18:00 (Lot number: EL3302) as dose 1, single for Covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: MIGRAINE (non-serious) with onset 08Feb2021, outcome "not recovered", described as "migraine headaches"; VISION BLURRED (non-serious) with onset 08Feb2021, outcome "not recovered", described as "blurred vision"; VISUAL IMPAIRMENT (non-serious) with onset 08Feb2021, outcome "not recovered", described as "seeing spots". The events "migraine headaches", "blurred vision" and "seeing spots" were evaluated at the physician office visit. Therapeutic measures were not taken as a result of migraine, vision blurred, visual impairment. Additional Information: The patient had no COVID prior vaccination. The patient did not receive any other vaccines within 4 weeks prior to COVID vaccine. The patient did not receive any other vaccinations or medication within 2 weeks. The patient did not receive other vaccine in four weeks. The patient was not tested for COVID post vaccination. Patient had no known allergies. No follow-up attempts are possible. No further information is expected.
Broke out in hives on both hands and left elbow. Scalp is also itchy. Itchiness gradually increased throughout the day until I took a Benadryl at 3pm and it mostly went away about 30 minutes later.
Developed a small rash (red itchy bumps)1 week after covid vaccine. 2 weeks later it spread down my arms, legs and torso. Seems to go away with antihistamines, the reactions happen off and on.
Pfizer-BioNTech COVID-19 Vaccine EUA Day 1. Soreness at the injection site.  Fatigue starting a few hours after the shot, lasting for over a week.  Day 4. Chills for a day.  Achiness lasting a week.  Supraclavicular lymph node by my left collar bone became tender and swollen, lasting over three weeks.  (Note this was the same side as the shot.  The healthcare worker injected the shot very high on the corner of my shoulder, almost on top of my shoulder.)  Runny nose.  Scratchy throat.   Day 5. Nausea lasting for two days. Day 7. Lymph node in my left armpit became tender and swollen.  I couldn't close my arm without causing pain to the lymph node in my left armpit.  Day 9. Chills again for a day.   Day 10. Another lymph node by my left collar bond became tender and swollen, lasting over three weeks.  The other swollen lymph nodes grew in size.  (In total, two lymph nodes by my left collarbone and one lymph node in my left armpit became tender and swollen.)   Period came two days early.  It was very heavy and included unusually large clots that were larger than a silver dollar.
7 hours after receiving 6 immunizations, patient had 3 minute generalized seizure witnessed by mother.  Transported by ambulance to ED where evaluation ensued and was negative after exam and blood work up. Diagnosis: Presumed febrile seizure.
This case was reported by a pharmacist and described the occurrence of thrush in a 77-year-old male subject who was vaccinated with Influenza vaccine unspecified (manufacturer unspecified). In 2010, the subject received an unspecified dose of Influenza vaccine unspecified (unknown route and injection site, batch number not provided). Within 12 hours after vaccination with Influenza vaccine unspecified, the subject experienced dry mouth, thrush, mouth sores, headache and lethargy. The events occurred intermittently for several months. The pharmacist considered the events were disabling. At the time of reporting, the events were mostly resolved. The dry mouth was improved but the subject still experienced it on occasion (not as severe as it was in the beginning). The pharmacist considered the events were probably related to vaccination with Influenza vaccine unspecified.
This case was reported by a pharmacist and described the occurrence of red rash injection site in a subject of unspecified age and gender who was vaccinated with FLUARIX (GlaxoSmithKline). In October 2008, the subject received a dose of FLUARIX (.5 ml, unknown). In October 2008, at an unspecified time after vaccination with FLUARIX, the subject experienced red rash injection site and pharmaceutical product complaint. The pharmacist received a call from a nurse at a nursing home facility that reported that 80 out of 100 subjects developed a "grapefruit size bright red" rash at the injection site. At the time of reporting the outcome of the events were unspecified. For the other 79 linked subjects please see cases: A0756483A - A0756561A. The CRC provided lot number AFLUA3208A to QA regarding this product complaint, while the report received in CMG Safety stated AFLUA3508A. With a possibility of a coding mistake to batch AFLUA320AA and on the basis that there are 80 cases out of 100, it was decided to ask for a Quality investigation (including cold chain) of all three batches (correct numbers: AFLUA350BA, AFLUA320BA and AFLUA320AA). On 16 January 2009, QA results were received for batches reviewed of (AFLUA320AA and AFLUA320BA): AFLUCA320, AFLUA320A, and AFLUA320B. The report indicated that no deviation that could be linked to the complaint and no cold chain deviation was recorded on the batches AFLUA320AA and AFLUA320BA. On 26 March 2009, QA results were received for batches reviewed (AFLUA350BA): AFLUCA350 and AFLUA350B. The reporter indicated that no deviation that could be linked to the complaint and no cold chain deviation was recorded on the batch AFLUA350BA.
PARENT CONTACTED THE ON-CALL DOCTOR AND MET HIM AT THE HOSPITAL WHILE HE WAS DOING ROUNDS. PT PRESENTED WITH SWELLING FROM MID-ARM TO ELBOW, REDNESS AND HEAT. THE DOCTOR PRESCRIBED KEFLEX AND ORAPRED.
2mins post vaccination pt c/o nausea. Vitals: 9:35 103/50, 75, 18, 100%, 98.0F -- > 9:45 103/60, 70, 17, 100% Pt stable and released from the vaccination site.
HCP reports that the patient has not experienced any symptoms.; HCP called to report that an expired dose of PROQUAD was given to a patient today 8/9/2023. Expiration date of PROQUAD 4/6/2023. HCP reports no previous TEs reported on product.  HCP reports that the patient has not experienced any symptoms. HCP gave; This spontaneous report was received from a nurse and  refers to a patient of unknown age and gender. There was no information about the patient's concurrent conditions or medical history provided. Concomitant medication included sterile diluent.  On 09-AUG-2023, the patient was vaccinated with measles, mumps, rubella and varicella (oka-merck) virus vaccine live (PROQUAD) injection, 0.5 milliliter, lot #U031563 was valid, expiration date established as 06-APR-2023, therapy type rHA for prophylaxis (expired product administered). The reporter stated that the patient had not experienced any symptoms (no adverse event).